SPRINT: What Remains Unanswered and Where Do We Go from Here?

Hypertension

Volumn 67, Issue 2, 2016, Pages 261-262

  Jones, Daniel W ^a   Weatherly, Lyssa ^a   Hall, John E ^a  

^a UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORTALIDONE; HYDROCHLOROTHIAZIDE; ANTIHYPERTENSIVE AGENT;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DYSLIPIDEMIA; HEART FAILURE; HUMAN; HYPERTENSION; NOTE; OBESITY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; BLOOD PRESSURE; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84954373410     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.115.06723     Document Type: Note

References (7)

1. SPRINT Research Group, Wright JT Jr, Williamson JD, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103-2116. doi: 10.1056/NEJMoa1511939.
2. Mancia G, Grassi G. Aggressive blood pressure lowering is dangerous: the J-curve: pro side of the arguement. Hypertension. 2014;63:29-36. doi: 10.1161/01.hyp.0000441190.09494.e9.
3. The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010:362:1575-1585.
4. Mancia G, Fagard R, Narkiewicz K, et al; Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013:31:1281-1357. doi: 10.1097/01. hjh.0000431740.32696.cc.
5. American Diabetes Association. Standards if medical care in diabetes-2015. Diabetes Care. 2015;38(suppl 1):S1-S93.
6. Mancia G. Effects of intensive blood pressure control in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation. 2010;122:847-849. doi: 10.1161/CIRCULATIONAHA.110.960120.
7. Lüders S, Schrader J, Berger J, Unger T, Zidek W, Böhm M, Middeke M, Motz W, Lübcke C, Gansz A, Brokamp L, Schmieder RE, Trenkwalder P, Haller H, Dominiak P; PHARAO Study Group. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens. 2008;26:1487-1496. doi: 10.1097/HJH.0b013e3282ff8864.